文献速递复苏、休克与脓毒症消化、代谢与肾脏急症重症综合管理与镇静镇痛

脓毒性休克患者细胞周期停滞标志物[TIMP-2]·[IGFBP7]的连续测量与进展至死亡、透析或严重急性肾损伤的风险

Serial Measurement of Cell-Cycle Arrest Biomarkers [TIMP-2] · [IGFBP7] and Risk for Progression to Death, Dialysis, or Severe Acute Kidney Injury in Patients with Septic Shock.
PubMed 文献 · Am J Respir Crit Care Med · 2020-01-01
一句话结论脓毒性休克患者复苏后尿[TIMP-2]·[IGFBP7]由阴转阳提示7天内死亡、透析或3期AKI风险升高约3倍,由阳转阴则风险降低。

该研究纳入ProCESS试验中688例脓毒性休克患者,在6小时复苏前后测量尿[TIMP-2]·[IGFBP7]。主要终点为7天内3期急性肾损伤、肾脏替代治疗或死亡,共113例(16.4%)达到。基线阴性而复苏后转阳者风险显著高于持续阴性者(21.8% vs 8.5%;OR 3.0)。基线阳性而复苏后转阴者风险低于持续阳性者(23.8% vs 9.8%;OR 2.15)。复苏后标志物阳性与更差结局相关,且不同复苏方案未改变标志物轨迹或患者结局,但标志物轨迹与结局相关。

要点

  • 基线[TIMP-2]·[IGFBP7]阴性、复苏后转阳(>0.3 U)者7天内3期AKI、透析或死亡风险为21.8%,持续阴性者为8.5%(OR 3.0;95%CI 1.31-6.87;P=0.01)。
  • 基线阳性、复苏后转阴者风险为9.8%,持续阳性者为23.8%(OR 2.15;95%CI 1.17-3.95;P=0.01)。
  • 复苏后[TIMP-2]·[IGFBP7]阳性在当时有或无AKI的患者中均与更差结局相关。
  • 复苏临床反应(APACHE II评分判断)对终点的预测能力较弱(AUC 0.68;95%CI 0.62-0.73),加入[TIMP-2]·[IGFBP7]后改善至0.72(95%CI 0.66-0.77;P=0.03)。
  • 不同复苏方案未改变标志物轨迹,也未改变标志物阳性或阴性患者的结局。

适用人群与场景

  • 纳入ProCESS试验的688例脓毒性休克患者,在6小时复苏前后测量尿[TIMP-2]·[IGFBP7]。

诊断标准与关键阈值

  • 尿[TIMP-2]·[IGFBP7]阳性定义为>0.3 U。
  • 主要终点为7天内3期急性肾损伤、肾脏替代治疗或死亡。

研究设计与关键结果

  • 研究类型为对ProCESS试验患者的标志物连续测量分析,样本量688例,人群为脓毒性休克患者,干预为6小时复苏前后测量尿[TIMP-2]·[IGFBP7],主要终点为7天内3期AKI、肾脏替代治疗或死亡,共113例(16.4%)达到终点。
  • 基线阴性而复苏后转阳者终点发生率21.8%,持续阴性者8.5%(P=0.01;OR 3.0;95%CI 1.31-6.87)。
  • 基线阳性而复苏后转阴者终点发生率9.8%,持续阳性者23.8%(P=0.01;OR 2.15;95%CI 1.17-3.95)。
  • 复苏后标志物阳性在当时有或无AKI的患者中均与更差结局相关。
  • 以APACHE II评分判断的复苏临床反应对终点的预测AUC为0.68(95%CI 0.62-0.73),加入[TIMP-2]·[IGFBP7]后AUC为0.72(95%CI 0.66-0.77;P=0.03)。
  • 不同复苏方案未改变标志物轨迹,也未改变标志物阳性或阴性患者的结局;但标志物轨迹与结局相关。

证据类型、等级与局限

  • 证据类型为对ProCESS随机对照试验患者的标志物分析;局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,初始液体复苏后尿[TIMP-2]·[IGFBP7]的变化可识别脓毒性休克患者中急性肾损伤进展风险不同的群体。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: Urinary TIMP-2 (tissue inhibitor of metalloproteinases-2) and IGFBP7 (insulin-like growth factor-binding protein 7) can predict acute kidney injury (AKI) in patients with sepsis.Objectives: To address critical questions about whether biomarkers can inform the response to treatment and whether they might be used to guide therapy, as most sepsis patients present with AKI.Methods: We measured [TIMP-2] · [IGFBP7] before and after a 6-hour resuscitation in 688 patients with septic shock enrolled in the ProCESS (Protocol-based Care for Early Septic Shock) trial. Our primary endpoint was stage 3 AKI, renal replacement therapy, or death within 7 days.Measurements and Main Results: The endpoint was reached in 113 patients (16.4%). In patients with negative [TIMP-2] · [IGFBP7] at baseline, those who became positive (>0.3 U) after resuscitation had three-times higher risk compared with those who remained negative (21.8% vs. 8.5%; P = 0.01; odds ratio [OR], 3.0; 95% confidence interval [CI], 1.31-6.87). Conversely, compared with patients with a positive biomarker at baseline that were still positive at Hour 6, risk was reduced for patients who became negative (23.8% vs. 9.8%; P = 0.01; OR, 2.15; 95% CI, 1.17-3.95). A positive [TIMP-2] · [IGFBP7] after resuscitation was associated with worse outcomes in both patients with and without AKI at that time point. The clinical response to resuscitation, as judged by the Acute Physiology and Chronic Health Evaluation II score, was weakly predictive of the endpoint (area under the curve, 0.68; 95% CI, 0.62-0.73) and improved with addition of [TIMP-2] · [IGFBP7] (0.72; 95% CI, 0.66-0.77; P = 0.03). Different resuscitation protocols did not alter biomarker trajectories, nor did they alter outcomes in biomarker-positive or biomarker-negative patients. However, biomarker trajectories were associated with outcomes.Conclusions: Changes in urinary [TIMP-2] · [IGFBP7] after initial fluid resuscitation identify patients with sepsis who have differing risk for progression of AKI.Clinical trial registered with www.clinicaltrials.gov (NCT00510835).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Fiorentino M, Xu Z, Smith A, et al. Serial Measurement of Cell-Cycle Arrest Biomarkers [TIMP-2] · [IGFBP7] and Risk for Progression to Death, Dialysis, or Severe Acute Kidney Injury in Patients with Septic Shock. Am J Respir Crit Care Med. 2020. PMID: 32584598. doi:10.1164/rccm.201906-1197OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。